STENTYS: Revenues for the Third Quarter of 2017: Continued Growth for the Xposition S Stent

  • Quarterly sales of the Xposition S stent up +19% in volume
  • Third quarter revenues: €1.6 million (-4.7%)

PARIS--(BUSINESS WIRE)--Regulatory News:


STENTYS (Paris:STNT) (FR0010949404 – STNT), a medical technology company
commercializing the Xposition S self-apposing coronary stent, today
reports its revenues for the third quarter and first nine months of 2017.

Change in revenues

    9 months   3rd quarter
€ thousands 2017   2016   % change 2017   2016   % change
Revenues* 5,162.40   5,337.90   -3.2% 1,614.80   1,693.50   -4.7%

* Unaudited data

During the third quarter of 2017, STENTYS recorded revenues of €1.6
million, down 4.7% compared to the same period of 2016. This slight
decrease is linked to the end of the commercialization of
previous-generation stents (SES / PES), which could not be entirely
offset despite a sound increase in sales of the Xposition S stent (+19%
in volume and +4% in value). The self-apposing Sirolimus-eluting stent
now accounts for 90% of the Company’s total revenues, as of September
30, 2017.

Over the first nine months of 2017, sales totaled €5.2 million, down
3.2% compared to the first nine months of 2016.

Christophe Lottin, Chief Executive Officer of STENTYS, comments: During
the third quarter, we have continued our efforts to rationalize our
offer, which is now primarily based on our flagship product, the
Xposition S stent. The continuous growth in sales since its launch
confirms its added value compared to conventional stents. We are
intensively working to accelerate its adoption in strategic countries
through a specific training program devoted to new users, while pursuing
its regulatory approval in new countries in order to stimulate our
growth from 2018.

About STENTYS
STENTYS develops and commercializes innovative
solutions for the treatment of patients with complex artery disease.
STENTYS’ Self-Apposing® drug-eluting stents are designed to
adapt to vessels with ambiguous or fluctuating diameters in order to
prevent the malapposition problems associated with conventional stents.
The APPOSITION clinical trials for the treatment of acute myocardial
infarction showed a very low mortality rate at one year and a faster
arterial healing compared to conventional stents. The company’s product
portfolio also includes MiStent SES®, a coronary DES whose
new drug delivery mechanism is designed to match vessel response, and is
marketed through STENTYS’ commercial network in Europe, the Middle East,
Asia and Latin America.
Additional information is available at
www.stentys.com

STENTYS is listed on Compartment C of Euronext Paris
ISIN:
FR0010949404 – Ticker: STNT

Safe Harbor Statements
This press release contains
forward-looking statements about the Company that are based on numerous
assumptions regarding the Company’s present and future business
strategies and the environment in which it will operate in the future
which may not be accurate. Such forward-looking statements involve known
and unknown risks which may cause the Company’s actual results,
performance or achievements to differ materially from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Such factors include, among others, risks
associated with the development and commercialization of the Company’s
products, market acceptance of the Company’s products, its ability to
manage growth, the competitive environment in relation to its business
area and markets, its ability to enforce and protect its patents and
proprietary rights, uncertainties related to the U.S. FDA approval
process, slower than expected rates of patient recruitment for clinical
trials, the outcome of clinical trials, and other factors, including
those described in the Section 4 “Risk Factors” of the Company’s 2015
Registration Document (document de référence) filed with the
French Autorité des Marchés Financiers (AMF) on August 30, 2016
under number D.16-804.


Contacts

STENTYS
André Lerebours
CFO
Tel.: +33 (0)1 44 53
99 42
investor@stentys.com
or
NewCap
Investor
Relations / Strategic Communications
Dusan Oresansky / Alexia Faure
Tel.:
+33 (0)1 44 71 94 92
stentys@newcap.eu